 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...128129130131132133134135136137138...236237» |
- oxaliplatin / Generic mfg.
[VIRTUAL] Dynamic changes of pro-angiogenic factors during FOLFIRI-aflibercept treatment: Interim analysis of DISTINCTIVE trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1822;
P=N/A
RAS wt mCRC pts progressing on first-line oxaliplatin-based + anti-EGFR are treated with second-line FOLFIRI-aflibercept... Change of pro-angiogenic factors during FOLFIRI-aflibercept might be a promising predictive factor for treatment efficacy.
- Avastin (bevacizumab) / Roche
[VIRTUAL] Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1811;
treatment with BRAF inhibitors and anti-EGFR antibodies shows the same efficacy as in BEACON study in pts with mutant BRAF mCRC in real clinical practice. However, there were no survival benefit in comparison with another systemic treatment in the 2nd line, this suggests we need a prospective randomized study to compare BRAF inhibitors combinations and chemotherapy with anti-VEGF agents in the 2nd line of treatment.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Zelboraf (vemurafenib) / Roche
[VIRTUAL] A study of vemurafenib and cetuximab in combination with FOLFIRI for patients with BRAF V600E-mutated advanced colorectal cancer (NCT03727763): Preliminary results () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1804;
P2
A combination of vemurafenib, cetuximab and FOLFIRI was generally well-tolerated and the preliminary result indicated considerably increased response rate for advanced colorectal cancer patients with BRAF V600E mutation. The enrollment for the trial is still under way.
- Avastin (bevacizumab) / Roche
[VIRTUAL] First line treatment patterns in BRAFV600E-mutant metastatic colorectal cancer patients (mCRC): The CAPSTAN European retrospective study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1801;
Treatment duration for these patients was short and highlights the aggressive nature of BRAFMT mCRC. The incidence of MSI patients identified is in line with recent data suggesting approximately 20% of BRAFMT patients have a high level of MSI.
- tremelimumab (CP-675206) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
[VIRTUAL] Durvalumab and tremelimumab in combination with FOLFOX in patients with previously untreated RAS-mutated metastatic colorectal cancer: First results of efficacy at one year for phase II MEDITREME trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1796;
P1/2
The combination showed PFS rates similar to PFS rates with chemotherapy doublet plus target therapies but with the advantage of only 3 months of chemotherapy. Translational data are being analysed to identify which patients could benefit from such therapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1792;
P2
Translational data are being analysed to identify which patients could benefit from such therapy. Although the cetuximab maintenance arm did not meet the primary objective, a clinically meaningful difference in PFS in favor of cetuximab maintenance was found in RAS/BRAF wt mCRC patients.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Cetuximab could be administered once every two weeks instead of once weekly () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1788;
P2
Our model allowed quantifying EGFR kinetics over time, which was associated to PFS. Our simulations suggested that a 500mg/m2 Q2W regimen could be used instead of 250mg/m2 QW in some patients.
- Avastin (bevacizumab) / Roche
[VIRTUAL] From clinical trial to bedside: Triplet chemotherapy (FOLFOXIRI-B) in metastatic colorectal cancer () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1786;
Considering most medical oncologists report to discuss this treatment option, the prescription rate is below what would be expected considering the 4.9 month survival benefit with FOLFOXIRI-B treatment. We show that awareness of guidelines and trial data contributes to the discussion of available treatment options by medical oncologists, emphasizing the need for repeated and continuing medical education.
- Avastin (bevacizumab) / Roche
[VIRTUAL] FOLFIRINOX with or without targeted therapy as first line for metastatic colorectal cancer: An AGEO multicenter real-world study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1784;
All treatment regimens seemed similarly effective when well adapted to the RAS status. In BRAF-mutated pts, the adjunction of anti-VEGF to TC does not show significant effect on this small population but needs to be evaluated in further prospective trials.
- Vectibix (panitumumab) / Amgen, Takeda
[VIRTUAL] Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1779;
P2
In BRAF-mutated pts, the adjunction of anti-VEGF to TC does not show significant effect on this small population but needs to be evaluated in further prospective trials. Second-line FOLFIRI + P beyond progression to FOLFOX + P deserves further investigation in RAS wild-type mCRC pts selected by LB.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., capecitabine / Generic mfg.
[VIRTUAL] Does adjuvant chemotherapy compared to surveillance improve recurrence free and overall survival in stage 3 rectal cancer patients? () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1777;
Surveillance may avoid chemotherapy related toxicities without compromising survival. Randomised trials are necessary to address this important issue.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCER PRODIGE-28 trial (Channel 4) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1338;
P2
Randomised trials are necessary to address this important issue. This exploratory analysis suggests that patients with any tumour mutation in MAPK pathway genes are not good candidates for maintenance treatment with cetuximab or treatment interruption after first-line FOLFIRI-cetuximab.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
[VIRTUAL] Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group (Channel 1) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1201;
P2
In the phase II NIFE trial nal-IRI/5-FU/LV showed efficacy as 1st-line treatment of advanced BTC with no new safety findings. ECCA and ICCA responded differently to drug interventions, with a clear benefit for nal-IRI/5-FU/LV in ECCA.
- Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
[VIRTUAL] Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217) (Channel 1) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1199;
P2
Trast/nivo/FOLFOX showed increased efficacy compared to the ToGA regimen, whereas trast/nivo/ipi did not improve OS over trast/chemo. Subgroupanalyses are ongoing and will be presented.
- Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
[VIRTUAL] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO (Channel 2) - Jul 22, 2021 - Abstract #ESMO2021ESMO_1026;
P2
While the magnitude of benefit is significantly higher in dMMR tumors, signals of efficacy are reported also in the pMMR subgroup. Translational analyses to identify predictive biomarkers are ongoing.
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., paclitaxel / Generic mfg.
Clinical: SWOG S1922 (FOLFIRI vs Ram/Taxol for 2nd+ line advanced small bowel adenocarcinoma) continues to accrue. Please consider enrolling eligible patients to this important study! #SBA #SWOG #Alliance #ECOGAcrin #NRG #supportrarecancertrials https://t.co/LScGBLax0j (Twitter) - Jul 21, 2021
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma. (Pubmed Central) - Jul 21, 2021
Translational analyses to identify predictive biomarkers are ongoing. Wait times from clinical presentation to beginning of chemotherapy do not influence survival in advanced PDAC.
- || oxaliplatin / Generic mfg.
Clinical, Journal, Circulating tumor DNA: "Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". (Pubmed Central) - Jul 21, 2021
P=N/A
Patients aged 18 to 75 years with ECOG performance status ≤1 with R0 surgical resection of a pT3-T4aN0 colon or high rectum adenocarcinoma will be randomized within 63 days after curative-intent surgery, to adjuvant mFOLFOX6 (oxaliplatin 85 mg/m², leucovorin 400 mg/m², and 5-FU bolus 400 mg/m2 then 5FU Continuous infusion 2.4 g/m²) every two weeks for 12 cycles or observation...Secondary endpoints include 2-yr DFS, overall survival, and toxicity. Recruitement began End of January 2020.
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Review, Journal, BRCA Biomarker, MSi-H Biomarker: How I treat pancreatic cancer. (Pubmed Central) - Jul 21, 2021
First-line and second-line chemotherapy does improve quality of life and OS in the metastatic setting, FOLFIRINOX and gemcitabine + nab-paclitaxel being the two current standard first-line options. Molecular profiling of metastatic patients is emerging, as some personalised therapies are possible for rare subtypes such as MSI high, BRCA1-2 mutated and NRG1/NTRK fusion gene PA.
- || nintedanib / Generic mfg.
Clinical, P2 data, Journal: Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: the randomized, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). (Pubmed Central) - Jul 21, 2021
Toxicity was moderate and only different for neutropenia (F+P: 11.5%, F+N: 19.2%) and gastrointestinal disorders (F+P: 65.4%, F+N: 84.6%). Final results show safety and a non-significant trend towards improved PFS and DCR for the combination of mFOLFOX6+nintedanib in the 2nd-line therapy of mCRC.
- || Avastin (bevacizumab) / Roche
Clinical, Journal: Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. (Pubmed Central) - Jul 21, 2021
Chemotherapeutic efficacy did not differ between the groups. Grade 3 or 4 AEs within the first four cycles of treatment and prior BEV exposure may be an effective predictor of treatment efficacy in mCRC patients administered VEGF inhibitors as second-line chemotherapy.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Journal: Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer: A Letter to the Editor. (Pubmed Central) - Jul 21, 2021
Grade 3 or 4 AEs within the first four cycles of treatment and prior BEV exposure may be an effective predictor of treatment efficacy in mCRC patients administered VEGF inhibitors as second-line chemotherapy. No abstract available
- Opdivo (nivolumab) / BMS
Phase classification: Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Jul 21, 2021
P1, N=36, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
No abstract available Phase classification: P1/2 --> P1
- | elimusertib (BAY 1895344) / Bayer
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines (clinicaltrials.gov) - Jul 21, 2021
P1, N=90, Recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1/2 --> P1 Not yet recruiting --> Recruiting | Trial completion date: Oct 2024 --> Dec 2022 | Trial primary completion date: Oct 2024 --> Dec 2022
- | Enrollment open: MRI-ENHANCE: MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer (clinicaltrials.gov) - Jul 20, 2021
P1, N=22, Recruiting, Sponsor: Medical College of Wisconsin
Not yet recruiting --> Recruiting | Trial completion date: Oct 2024 --> Dec 2022 | Trial primary completion date: Oct 2024 --> Dec 2022 Not yet recruiting --> Recruiting
- || Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Journal, Liquid biopsy: Amplification of mutant KRAS in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report. (Pubmed Central) - Jul 20, 2021
Subsequent treatment with gemcitabine plus nab-paclitaxel failed to control the disease...Overall, amplification of oncogenic KRAS was not only associated with an aggressive phenotype, but also supported cancer resistance to chemotherapy. Importantly, this case suggests that plasma detection of KRAS amplification is feasible in the clinical routine and constitutes a powerful tool for assessing tumor aggressiveness.
- Avastin (bevacizumab) / Roche
[VIRTUAL] FIRST-LINE PALLIATIVE SYSTEMIC THERAPY ALTERNATED WITH ELECTROSTATIC PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY (OXALIPLATIN) FOR ISOLATED UNRESECTABLE COLORECTAL PERITONEAL METASTASES: A MULTICENTRE, SINGLE-ARM, PHASE II STUDY (CRC-PIPAC-II). (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_4677;
Patients receive three cycles of bidirectional therapy, consisting of six weeks first-line palliative systemic therapy at medical oncologists’ discretion (CAPOX-bevacizumab, FOLFOX-bevacizumab, FOLFIRI-bevacizumab, or FOLFOXIRI-bevacizumab) and is followed by electrostatic PIPAC-OX (92 mg/m2) with intraoperative bolus of intravenous leucovorin (20 mg/m2 ) and 5-fluorouracil (400 mg/m2 ). Bidirectional therapy consisting of first-line palliative systemic therapy alternated with ePIPAC-OX appears feasible and safe in patients with unresectable, isolated colorectal peritoneal metastases, justifying trial continuation.
- oxaliplatin / Generic mfg.
[VIRTUAL] TRACKING GENETIC AND TRANSCRIPTOMIC CHANGES IN OESOPHAGEAL ADENOCARCINOMA DURING NEOADJUVANT TREATMENT (Hall 4) - Jul 20, 2021 - Abstract #UEGW2021UEGW_3997;
P2
Moreover our data suggests that such treatment leads to major alterations in key signalling networks of OAC cells, and also affects the immune architecture of the tumour microenvironment. Together the data are consistent with phenotypic plasticity of tumour cells as a determinant of response to treatment.
- Avastin (bevacizumab) / Roche
[VIRTUAL] FIRST-LINE PALLIATIVE SYSTEMIC THERAPY ALTERNATED WITH ELECTROSTATIC PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY (OXALIPLATIN) FOR ISOLATED UNRESECTABLE COLORECTAL PERITONEAL METASTASES: A MULTICENTRE, SINGLE-ARM, PHASE II STUDY (CRC-PIPAC-II). (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_2497;
Patients receive three cycles of bidirectional therapy, consisting of six weeks first-line palliative systemic therapy at medical oncologists’ discretion (CAPOX-bevacizumab, FOLFOX-bevacizumab, FOLFIRI-bevacizumab, or FOLFOXIRI-bevacizumab) and is followed by electrostatic PIPAC-OX (92 mg/m2) with intraoperative bolus of intravenous leucovorin (20 mg/m2 ) and 5-fluorouracil (400 mg/m2 ). Bidirectional therapy consisting of first-line palliative systemic therapy alternated with ePIPAC-OX appears feasible and safe in patients with unresectable, isolated colorectal peritoneal metastases, justifying trial continuation.
- Avastin (bevacizumab) / Roche
[VIRTUAL] FOLFOX-BEVACIZUMAB CHEMOTHERAPY IN PATIENTS WITH PROGRESSIVE METASTATIC NEUROENDOCRINE TUMORS: Discussion (Hall 7) - Jul 20, 2021 - Abstract #UEGW2021UEGW_1435;
- Avastin (bevacizumab) / Roche
[VIRTUAL] FOLFOX-BEVACIZUMAB CHEMOTHERAPY IN PATIENTS WITH PROGRESSIVE METASTATIC NEUROENDOCRINE TUMORS (Hall 7) - Jul 20, 2021 - Abstract #UEGW2021UEGW_1434;
The FOLFOX-bevacizumab combination has promising efficacy in patients with progressive metastatic NETs, notably in those with G3 NETs, for which optimal treatment is ill-defined yet. Hence, it could be a relevant alternative to alkylating-based chemotherapy in this setting and should be further explored prospectively.
- Avastin (bevacizumab) / Roche
[VIRTUAL] FIRST-LINE PALLIATIVE SYSTEMIC THERAPY ALTERNATED WITH ELECTROSTATIC PRESSURIZED INTRAPERITONEAL AEROSOL CHEMOTHERAPY (OXALIPLATIN) FOR ISOLATED UNRESECTABLE COLORECTAL PERITONEAL METASTASES: A MULTICENTRE, SINGLE-ARM, PHASE II STUDY (CRC-PIPAC-II). (Poster Exhibition) - Jul 20, 2021 - Abstract #UEGW2021UEGW_666;
Patients receive three cycles of bidirectional therapy, consisting of six weeks first-line palliative systemic therapy at medical oncologists’ discretion (CAPOX-bevacizumab, FOLFOX-bevacizumab, FOLFIRI-bevacizumab, or FOLFOXIRI-bevacizumab) and is followed by electrostatic PIPAC-OX (92 mg/m2) with intraoperative bolus of intravenous leucovorin (20 mg/m2 ) and 5-fluorouracil (400 mg/m2 ). Bidirectional therapy consisting of first-line palliative systemic therapy alternated with ePIPAC-OX appears feasible and safe in patients with unresectable, isolated colorectal peritoneal metastases, justifying trial continuation.
- | 5-fluorouracil / Generic mfg.
Trial completion, Trial completion date, Metastases: Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (clinicaltrials.gov) - Jul 20, 2021
P1, N=14, Completed, Sponsor: Virginia Commonwealth University
Bidirectional therapy consisting of first-line palliative systemic therapy alternated with ePIPAC-OX appears feasible and safe in patients with unresectable, isolated colorectal peritoneal metastases, justifying trial continuation. Active, not recruiting --> Completed | Trial completion date: May 2023 --> May 2021
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Metastases: NIFTY: Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jul 20, 2021
P2, N=178, Active, not recruiting, Sponsor: Changhoon Yoo
Active, not recruiting --> Completed | Trial completion date: May 2023 --> May 2021 Trial completion date: Jun 2021 --> Jun 2023
- | Enrollment open, Trial completion date, Trial primary completion date, Metastases: Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer (clinicaltrials.gov) - Jul 19, 2021
P3, N=388, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Trial completion date: Jun 2021 --> Jun 2023 Not yet recruiting --> Recruiting | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
- || oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., tegafur/uracil / Generic mfg.
Clinical, P2 data, Journal: Randomized phase II study of tegafur-uracil/leucovorin versus tegafur-uracil/leucovorin plus oxaliplatin after curative resection of high-risk stage II/III colorectal cancer (SOAC-1101 trial). (Pubmed Central) - Jul 18, 2021
Not yet recruiting --> Recruiting | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2023 TEGAFOX is an additional adjuvant chemotherapy option for high-risk stage II/III colorectal cancer.
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Journal: CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathway. (Pubmed Central) - Jul 18, 2021
In summary, our results showed that nab-paclitaxel increased the expression of CCL26 in CAFs, and CCL26 enhanced the invasive potential of pancreatic cancer cells by activating the PI3K/AKT/mTOR axis. Thus, CCL26 may be a potential prognostic biomarker for pancreatic cancer.
- || methotrexate / Generic mfg.
Clinical, Journal: Severe multiorgan toxicity after first dose of Capizzi methotrexate in a young adult patient with acute lymphocytic leukaemia. (Pubmed Central) - Jul 18, 2021
Capizzi methotrexate therapy implies no leucovorin therapy, hence putting patients at risk for multiorgan toxicity. Our experience reinforces the importance of close monitoring for patients receiving methotrexate, regardless of dose, and the prompt administration of high-dose leucovorin once toxicity suspected.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Clinical, Reimbursement, Journal, HEOR, Medicare, Real-world evidence: Real-World Cost of Care for Commercially Insured versus Medicare Patients with Metastatic Pancreatic Cancer Who Received Guideline-Recommended Therapies. (Pubmed Central) - Jul 17, 2021
We calculated the total cost of care and resource utilization by NCCN-recommended (category 1) treatment regimen, including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX); gemcitabine plus nab-paclitaxel; gemcitabine monotherapy; and liposomal irinotecan...The total costs of care were similar across the regimens in each cohort, but the components of the total cost varied. These results can inform clinical guidelines and pathways for pancreatic cancer therapy as new evidence and treatment options emerge, and in the context of increasing value-based care models.
- | methotrexate / Generic mfg.
Journal: Dihydrofolate Reductase Is a Valid Target for Antifungal Development in the Human Pathogen Candida albicans. (Pubmed Central) - Jul 17, 2021
Finally, we show that repression of DHFR in a mouse model of infection was sufficient to eliminate host mortality. Our work conclusively establishes DHFR as a valid antifungal target in C. albicans.
- ||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine (clinicaltrials.gov) - Jul 16, 2021
P2, N=1, Completed, Sponsor: HonorHealth Research Institute
Our work conclusively establishes DHFR as a valid antifungal target in C. albicans. Recruiting --> Completed | N=42 --> 1 | Trial completion date: Jul 2021 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. (Pubmed Central) - Jul 16, 2021
This study validates the GMS as a prognostic tool for patients with stage I-III colorectal cancer, independent of TNM, with the ability to stratify both low- and high-risk disease. Furthermore, GMS 0 could be employed to identify a subset of patients that benefit from FOLFOX over CAPOX.
- | Zepsun (donafenib) / Suzhou Zelgen
New P2 trial, Surgery: Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery (clinicaltrials.gov) - Jul 14, 2021
P2, N=30, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
[VIRTUAL] Double or nothing? Choice of first-line chemotherapy in a real world metastatic colorectal cancer cohort – results from the TRACC registry (Virtual Room 1) - Jul 14, 2021 - Abstract #MOGAASM2021MOGA_ASM_44;
Our local registry data supports this, despite prognostic factors biasing against FP alone. Use of triplet therapy, where an OS advantage has been demonstrated, is increasing.
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi, Avastin (bevacizumab) / Roche
Clinical: From my CRC clinic plus RWE from @flatironhealth Frontiers | Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) | Oncology https://t.co/FOoVWrxmO3 (Twitter) - Jul 14, 2021
- | Trial completion date: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Jul 14, 2021
P1, N=80, Not yet recruiting, Sponsor: Hoffmann-La Roche
Use of triplet therapy, where an OS advantage has been demonstrated, is increasing. Trial completion date: Jul 2023 --> Dec 2024
- | New P3 trial: HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC (clinicaltrials.gov) - Jul 13, 2021
P3, N=188, Recruiting, Sponsor: Shi Ming
- ||| Trial completion, Trial completion date, Combination therapy, Metastases: PanCO: A Pilot Study of OncoSil (clinicaltrials.gov) - Jul 13, 2021
P=N/A, N=50, Completed, Sponsor: OncoSil Medical Limited
Trial completion date: Jul 2023 --> Dec 2024 Active, not recruiting --> Completed | Trial completion date: Jul 2021 --> Jul 2020
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
https://t.co/fylG6Kj49Y… Old paper w statisti signif inc PFS when give leucovorin with 24h Inf 5FU C/w 24h inf 5FU alone; I think this is why some give Leucovorin even when no bolus 5FU. In previous Twitter discussions, Grothey seemed to be pro while others did not support. (Twitter) - Jul 12, 2021
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Resection and Reconstruction of a Replaced Common Hepatic Artery and Portal Vein During Pancreaticoduodenectomy. (Pubmed Central) - Jul 11, 2021
A large dorsal pancreatic artery arising from the SMA is used for the arterial reconstruction in this particular case. The approach used entails extensive bowel mobilization, mesenteric approach to the coelio-mesenteric vessels and arterial divestment making feasible arterial and venous resection with reconstruction without graft interposition.